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Background
Identification of cellular factors that negatively or posi-
tively regulate HIV-1 replication is essential to under-
stand HIV-1 pathogenesis for development of novel
antiviral treatments. The human cytidine deaminase
APOBEC3G (A3G) is an intrinsic antiviral factor impor-
tant for the host-mediated defence against HIV-1. We
and others recently identified a panel of A3G-interacting
RNA-binding proteins (RBPs) that focused our search
for novel HIV-1 cofactors and restriction factors onto
these proteins. Mov10, a superfamily-1 putative RNA
helicase, interacts with A3G in an RNA-dependent man-
ner. Mov10 associates with the RNA-induced silencing
complex pathway and localises to mRNA processing
bodies (PBs). Furthermore,o r t h o l o g so fM o v 1 0i nAra-
bidopsis thaliana and Drosophila melanogaster are
necessary for antiviral small RNA-mediated silencing.
Thus, we investigated whether Mov10 restricts HIV-1
replication.
Materials and methods
The effect of Mov10 on HIV-1 virus production and
ínfectivity was determined by ectopic expression and
silencing of Mov10 in virus-producing HeLa and 293T
cell lines. Cells were transfected with a plasmid encod-
ing the full-length HIV-1NL4-3 provirus or infected with
VSV-G pseudotyped HIV-1NL4-3 virus. Virion produc-
tion was measured by p24
Gag ELISA and infectivity was
determined by infecting a TZM reporter cell line with
virus normalised by p24
Gag concentration.
Results
The ectopic expression of Mov10 substantially decreased
HIV-1 virion infectivity, whilst moderately decreasing
virus production. Mov10 induced a significant reduction
in the accumulation of minus strand strong stop DNA
in the target cell, which likely accounted for the consid-
erable loss in virion infectivity. Preliminary results
showed a small decrease in HIV-1 genome incorpora-
tion into budding virions that may have contributed to
the defect at strong stop. Mov10 comprises a 495 resi-
due amino-terminal domain with no known protein
motifs, and a 508 residue carboxy-terminal putative
RNA helicase domain. To begin to identify important
attributes in Mov10 we mutated known helicase motifs
in the full-length protein; overexpression of these
mutants determined that the carboxy-terminal putative
RNA helicase domain of Mov10 is necessary for its anti-
viral activity. Furthermore, RNAi-mediated silencing of
endogenous Mov10 moderately enhanced HIV-1 virion
production with no discernable effect on virion infectiv-
ity. We also tested A3G antiviral activity in the context
of Mov10 silencing, which was unaffected.
Conclusions
Our findings indicate a potential antiviral role for
Mov10 in the HIV-1 life cycle, independent of A3G
antiviral activity. The effect of Mov10 silencing on HIV-
1 was modest, however, this is currently being addressed
in primary CD4
+T cells and macrophages, the natural
targets of HIV-1 infection. Furthermore, we are investi-
gating whether Mov10 is upregulated by type I inter-
feron and identifying molecular mechanism/s by which
Mov10 is able to inhibit HIV-1 infection.
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